Here are four observations:
1. NuVasive’s $0.32 EPS for the period ending March 31 checked within $0.05 of Wall Street analysts’ predictions.
2. Price Target Brokerage firm analysts predict NuVasive’s stock will hit $63.916 on a short-term basis.
3. The highest stock estimate reached $76 and the lowest estimate was $58.
4. Zacks gave NuVasive a rating of 1.27 (with one being a “strong buy” and five being a strong sell.”)
More articles on devices:
Open Payments data may need more nuance, S.C. physicians say — 5 notes
Stryker Q2 net sales jump 16.8% to $2.8B: 9 key notes
Zimmer Biomet, Medtronic, DePuy Synthes & more: 16 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
